Literature DB >> 8563894

Activation of eosinophils in the pathophysiology of ulcerative colitis.

K Makiyama1, S Kanzaki, K Yamasaki, W Zea-Iriarte, Y Tsuji.   

Abstract

We studied the role of eosinophils as effector cells in the pathophysiology of ulcerative colitis. In the active stage of this disease, the colonic mucosa exhibited infiltration of numerous eosinophils positive to the EG2 antibody, which reacts specifically with the secretory form of eosinophil cationic protein. Electron microscopic studies demonstrated that the eosinophils had specific granules in various stages of degranulation. Hence, it is strongly suggested that the eosinophils infiltrating the inflamed mucosa are activated and may induce tissue damage during the degranulation and release of this cationic protein. Changes in the levels of serum eosinophil cationic protein in 14 patients who remained for in long-term remission were studied. Four of these patients showed persistently high concentrations of eosinophil cationic protein (equal to or greater than 30 micrograms/l) and persistently high percentage (mean, 30.2%) of hypodense eosinophils (specific gravity < 1.082) in the peripheral blood. Such findings were associated with mild active disease at colonoscopy. These features suggest that the activation of eosinophils is one of the factors that contribute to the chronic inflammation in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563894

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  12 in total

1.  Eosinophil granulocytes are activated during the remission phase of ulcerative colitis.

Authors:  M Lampinen; A Rönnblom; K Amin; G Kristjansson; F Rorsman; P Sangfelt; B Säfsten; M Wagner; A Wanders; O Winqvist; M Carlson
Journal:  Gut       Date:  2005-05-10       Impact factor: 23.059

2.  Effects of sulfasalazine on biopsy mucosal pathologies and histological grading of patients with active ulcerative colitis.

Authors:  Ying-Qiang Zhong; Hua-Rong Huang; Zhao-Hua Zhu; Qi-Kui Chen; Jun Zhan; Lian-Chun Xing
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

3.  Eosinophil activation in ulcerative colitis: studies on mucosal release and localization of eosinophil granule constituents.

Authors:  Y Raab; K Fredens; B Gerdin; R Hällgren
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

4.  IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis.

Authors:  M Lampinen; M Carlson; P Sangfelt; Y Taha; M Thörn; L Lööf; Y Raab; P Venge
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

5.  Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats.

Authors:  Kazuko Shichijo; Kazuya Makiyama; Chun-Yang Wen; Mutsumi Matsuu; Toshiyuki Nakayama; Masahiro Nakashima; Makoto Ihara; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

6.  Bactericidal activity of human eosinophilic granulocytes against Escherichia coli.

Authors:  T Persson; P Andersson; M Bodelsson; M Laurell; J Malm; A Egesten
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis.

Authors:  Steven Maltby; Carolin Wohlfarth; Matthew Gold; Lori Zbytnuik; Michael R Hughes; Kelly M McNagny
Journal:  Am J Pathol       Date:  2010-08-09       Impact factor: 4.307

Review 8.  Eosinophilic esophagitis: an emerging clinicopathologic entity.

Authors:  Glenn T Furuta
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.806

9.  Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes.

Authors:  Tareq Taha Jubeh; Yechezkel Barenholz; Abraham Rubinstein
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

10.  Clinical value of serum eosinophilic cationic protein assessment in children with inflammatory bowel disease.

Authors:  Andrzej Wędrychowicz; Przemysław Tomasik; Stanisław Pieczarkowski; Kinga Kowalska-Duplaga; Zofia Grzenda-Adamek; Krzysztof Fyderek
Journal:  Arch Med Sci       Date:  2013-04-09       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.